282. Congenital dyserythropoietic anemia Disease details / Clinical trials / Drug dev / DR info
Clinical trial : 1 / Drug : 1 - (DrugBank : 1) / Drug target genes : 2 - Drug target pathways : 4
Congenital dyserythropoietic anemia and other diseases between which drug repositioning might occur (Sakate and Kimura 2021) . Circle size: Number of drugs, Line breadth: Drug repositionability
| ID | Diseases (Sorted by drug repositionability) |
|---|---|
| 282 | Congenital dyserythropoietic anemia |
| 13 | Multiple sclerosis/Neuromyelitis optica |
| 6 | Parkinson disease |
| 21 | Mitochondrial disease |
| 299 | Cystic fibrosis |
| 2 | Amyotrophic lateral sclerosis |
| 63 | Idiopathic thrombocytopenic purpura |
| 46 | Malignant rheumatoid arthritis |
| 51 | Scleroderma |
| 65 | Primary immunodeficiency |
| 85 | Idiopathic interstitial pneumonia |
| 86 | Pulmonary arterial hypertension |
| 96 | Crohn disease |
| 98 | Eosinophilic gastrointestinal disease |
| 222 | Primary nephrotic syndrome |
| 271 | Ankylosing spondylitis |
| 8 | Huntington disease |
| 113 | Muscular dystrophy |
| 107 | Juvenile idiopathic arthritis |
| 298 | Hereditary pancreatitis |
| 97 | Ulcerative colitis |
| 225 | Congenital nephrogenic diabetes insipidus |
| 166 | Pseudoxanthoma elasticum |
| 294 | Congenital diaphragmatic hernia |
| 71 | Idiopathic osteonecrosis of the femoral head |